Centogene NV (CNTG) News

CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE Announces Preliminary Full Year 2023 Revenue

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE Announces Voting Results of Extraordinary General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq:...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism

Collaborative research initiative leveraged CENTOGENE’s Whole Exome Sequencing (WES) to reveal disease-causing...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]